Z01 CP010176-10068 (Z01) | |||
---|---|---|---|
Title | Hemophilia studies | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Mbulaiteye, Sam | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $855,848 | Project Dates | 03/24/2004 - N/A |
Fiscal Year | 2008 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Autoimmune Diseases (40.0%) Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Liver Cancer (50.0%) Lymphoma (50.0%) Non Hodgkins Lymphoma (50.0%) |
||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
Data and specimens from the First and Second Multicenter Hemophilia Cohort Studies (MHCS-I/-II) will be used to elucidate rates, markers and risk factors for HCC among more than 4000 people with hemophilia. There are five attributes of these prospective studies. First, there are high rates of HCV, HBV and HIV co-infections. Second, ages at HCV and HIV (and probably HBV) infections can be imputed with reasonable precision. Third, there is a wide range of ages at infection. Fourth, there is moderate use of two hepatotoxins, alcohol and acetaminophen. And fifth, there are annually cryopreserved plasma and lymphocyte specimens to characterize changes in interim markers. The host immune response to HCV infection with HIV and/or HBV can be studied in this cohort of highly prevalent oncogenic coinfections. In addition to ESLD and HCC events (expected n=330 and 15, respectively), correlates of intermediate conditions (such as HCV and HBV viral loads determined by TaqMan) will be evaluated. Data and specimens from MHCS-I/-II will be also used to elucidate whether HCV viremia, viral load, or genotype are associated with NHL with or without HIV co-infection. |